Related Experiment Video
Updated: Jan 16, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
Reprogramming SUMO-primed ubiquitylation: opportunities in oncology and neurology
Gina Gotthardt1, Jan Keiten-Schmitz1, Stefan Müller1
1Goethe University Frankfurt, Faculty of Medicine, Institute of Biochemistry II, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
Abstract:
Drugs that reprogram the cellular ubiquitin-proteasome system for removal of disease-causing proteins hold great promise as a new type of pharmacology. Small ubiquitin-related modifier (SUMO)-targeted ubiquitin ligases (StUbLs) are E3 ubiquitin ligases that mediate ubiquitylation of proteins primed by modification with SUMO. The antineoplastic drugs arsenic trioxide and fulvestrant stand out as examples for leveraging a SUMOylation-ubiquitylation cascade to inactivate the oncogenic fusion proteins PML-RARα and estrogen receptor α, respectively. However, approaches harnessing the StUbL system for targeting a broader spectrum of disease-relevant proteins are missing. Recent proof-of-concept studies indicate that proximity-inducing modalities can recruit aggregation-prone proteins to the StUbL machinery, potentially mitigating the formation of neurotoxic inclusions. We review new insights on StUbL-based therapeutics and reflect perspectives of reprogramming SUMO-StUbL signaling for use in oncology and neurology.
More Related Videos
Related Concept Videos
Somatic to iPS Cell Reprogramming
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Methods of Nuclear Reprogramming
Introduction to Nuclear Reprogramming
Abnormal Proliferation
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...

